Bellevue Asset Management Ltd
Bellevue Asset Management and its sister company StarCapital based in Oberursel outside Frankfurt, Germany are part of Bellevue Group, an independent, Swiss financial group with a registered office in Zurich and a listing on the Swiss Exchange SIX. Bellevue was established in 1993 and has since become a leading investment boutique with a focus on healthcare, regional strategies, multi-asset solutions and global equity and bond funds. Total client assets amount to CHF 11.8 billion.
Both firms offer a well-diversified, complementary range of products and services. One of Bellevue’s core areas of expertise dating back more than 20 years is the global healthcare sector. Besides BB Biotech AG, an investment company included in the Stoxx Europe 600 Index, Bellevue offers a range of investment funds covering medical technology, biotechnology, generics and Asian healthcare themes. Bellevue ranks as one of Europe's largest investors in the healthcare sector.
Investment funds focused on structural growth stories in emerging markets such as Africa or that invest specifically in family and entrepreneur-owned companies listed on the stock market are another area of specialty at Bellevue.
Conservative return expectations coupled with minimal and strictly managed volatility risk are addressed by the Bellevue Global Macro Fund.
StarCapital's activities are guided by a holistic perspective of financial markets backed by proprietary capital market research. In addition to global equity and fixed income funds, its investment experts successfully manage multi-asset funds. A diverse family of ETF strategies (ETF-based asset allocation strategies) rounds out its holistic profile/OR/product platform.
The following product categories are offered
- Equity Regions
- Equity Sectors
- Liquid Alternatives
- Multi Asset
- Total Return / Absolute Return
Biotech-Investments: Milliardenmarkt Immuntherapien
Stoffwechselkrankheiten: Biotechnologie im Kampf gegen den Zucker
Bellevue Group steigert Kundenvermögen auf CHF 11.8 Mrd. und verdreifacht Konzerngewinn
Assets under management